1558.HK YiChang HEC (HKSE) HK$15.88 intraday 09 Jan 2026: oversold bounce
We see a clear intraday oversold bounce setup in 1558.HK stock after a pullback to HK$15.52 and a current trade at HK$15.88 on the HKSE on 09 Jan 2026. Volume is active at 19.31M versus an average of 9.30M, giving a relative volume of 2.08, which supports a short-term rebound thesis. Traders should note the tight intraday range (HK$15.52–HK$16.18) and use precise risk controls since fundamentals and sector trends matter for any hold beyond a bounce.
Intraday trade setup for 1558.HK stock
Price action shows a probe to the day low HK$15.52 followed by a recovery to HK$15.88, signalling a potential oversold bounce opportunity on the HKSE. The stock opened at HK$16.14 and trades below the 50-day average of HK$15.09, which supports a mean-reversion play in the short term.
Volume confirms the move: 19.31M shares traded today vs an average 9.30M, so intraday momentum favours buyers stepping in. Keep stops below HK$15.50 for tight risk control.
Key levels, volume and technicals for 1558.HK stock
Immediate resistance sits at the intraday high HK$16.18 and the 50-day average HK$15.09 is now near-term support turned resistance. Year high is HK$17.74 and year low is HK$7.92, giving a wide longer-term range.
On our trade time frame, watch a reclaim of HK$16.20 as a momentum trigger; failure to hold HK$15.50 would invalidate the oversold bounce. Note reported technical indicators are limited, so rely on price and volume reads for intraday execution.
Fundamentals snapshot and valuation for 1558.HK stock
YiChang HEC ChangJiang Pharma (1558.HK) reports EPS HK$0.60 and a trailing PE of 26.47, with market cap around HK$13.97B on the HKSE in Hong Kong. Book value per share is HK$9.67 and dividend per share TTM is HK$1.47, implying a dividend yield of 10.32% on historical payout metrics.
Key financial ratios: price-to-sales 3.36, price-to-book 1.47, current ratio 1.77, debt-to-equity 0.26, and free cash flow per share negative at -1.24. These mixed fundamentals support a tactical short-term trade rather than a blind buy-and-hold.
Meyka AI rates 1558.HK with a score out of 100
Meyka AI rates 1558.HK with a score out of 100: 69.79 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade flags solid profitability metrics but weaker cash flow and recent revenue declines.
Meyka AI’s forecast model projects a 1-year price of HK$15.75, a 3-year price of HK$20.52, and a 5-year price of HK$25.27. Forecasts are model-based projections and not guarantees.
Risks, catalysts and sector context for 1558.HK stock
Primary risks: FY 2024 revenue and net income contraction, stretched operating cash flow, and long receivables and inventory days (DSO 211.28, DIO 253.58). These raise working capital and execution risks for YiChang HEC on HKSE.
Catalysts include product approvals, stronger distributor agreements, and sector tailwinds in healthcare. The Healthcare sector average PE is around 31.33, so 1558.HK’s PE 26.47 is below sector average and may re-rate on positive operational updates.
Trading plan and price targets for 1558.HK stock
Short-term trade: buy on confirmation above HK$16.20 with a stop at HK$15.48 and a first target at HK$16.50 (implied upside 3.90%). A higher target for intraday momentum is HK$17.74 (year high) for traders willing to hold through volatility.
Longer-term model targets: Meyka short-run forecast HK$15.75 (1-year, implied -0.82% vs current), 3-year HK$20.52 (implied 29.22% upside), 5-year HK$25.27 (implied 59.13% upside). Use those as guideposts, not certainties.
Final Thoughts
We view 1558.HK stock as a tactical oversold bounce candidate on the HKSE on 09 Jan 2026 because of active intraday volume (19.31M), a clear intraday low at HK$15.52, and a current price of HK$15.88 that sits close to the 50-day average. For short-term traders we recommend a disciplined plan: confirm strength above HK$16.20, target HK$16.50 and limit risk with a stop under HK$15.50. From a fundamentals perspective the company posts a PE of 26.47, book value HK$9.67, and a high reported dividend per share HK$1.47, but cash flow weakness and declining FY 2024 revenue temper conviction.
Meyka AI’s forecast model projects HK$15.75 at one year and HK$20.52 at three years, implying modest short-term downside versus a multi-year upside of ~29.22%. These are model-based projections and not guarantees. Traders should combine intraday technical signals with the company’s financial trends and sector context before opening larger positions. For live updates see the company site and our stock page.
FAQs
Is 1558.HK stock a buy after today’s intraday pullback?
1558.HK stock shows a short-term buy setup if price reclaims HK$16.20 with volume support. Use a tight stop under HK$15.50 and treat any entry as a tactical trade, not a long-term commitment.
What are the main valuation metrics for 1558.HK stock?
Key metrics: PE 26.47, price-to-book 1.47, price-to-sales 3.36, book value per share HK$9.67, and dividend per share HK$1.47. Mixed metrics suggest value but watch cash flow weakness.
How does Meyka AI forecast 1558.HK stock?
Meyka AI’s forecast model projects HK$15.75 at one year and HK$20.52 at three years. These projections show modest short-term downside and multi-year upside and are model-based, not guarantees.
What risk controls should traders use on 1558.HK stock intraday?
Use a stop-loss near HK$15.50, position size capped at your risk tolerance, and avoid scaling in on poor volume. Confirm moves with volume above 9.30M average before adding.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
